Europe Breast Cancer Drug Pipeline Analysis

Publish Date:- Oct-2013       No Of Pages (380)

Electronic Access - Single User License $1800 Buy Now
CD-ROM Mail Delivery $2400Buy Now
Hard Copy Mail Delivery $2400 Buy Now
Electronic Access - Multi-User License $3000 Buy Now


The pharmaceutical companies have recently been focusing increasingly on women's health. Among the diseases specific to women, breast cancer has become one of the leading causes of death for the women population globally and accounts for almost 3 per cent of the causes of death in women. It has been estimated that one in every 12 women is most likely to develop breast cancer at some point in her life, owing to risk factors such as hormonal effects, age and genetic predisposition.

In Europe, breast cancer has been the most diagnosed form of cancer and the deaths due to this disease have increased by 16% during the previous two years. Though the incidence rate has significantly increased, on the other side, there has also been an increase of treatment and survival rates in the European region in the recent years.

Europe Breast Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Breast Cancer. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Breast Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Europe Breast Cancer Drug Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class • ATC Codes

Europe Breast Cancer Drug Pipeline by Clinical Phase:

• Unknown: 1

• Research: 5

• Preclinical: 10

• Clinical: 5

• Phase-I: 11

• Phase-I/II: 12

• Phase-II: 43

• Phase-II/III: 1

• Phase-III: 10

• Preregistration: 1

• Registered: 2

• Marketed: 30


The pharmaceutical companies have recently been focusing increasingly on women's health. Among the diseases specific to women, breast cancer has become one of the leading causes of death for the women population globally and accounts for almost 3 per cent of the causes of death in women. It has been estimated that one in every 12 women is most likely to develop breast cancer at some point in her life, owing to risk factors such as hormonal effects, age and genetic predisposition.

In Europe, breast cancer has been the most diagnosed form of cancer and the deaths due to this disease have increased by 16% during the previous two years. Though the incidence rate has significantly increased, on the other side, there has also been an increase of treatment and survival rates in the European region in the recent years.

Europe Breast Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Breast Cancer. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Breast Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Europe Breast Cancer Drug Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class • ATC Codes

Europe Breast Cancer Drug Pipeline by Clinical Phase:

• Unknown: 1

• Research: 5

• Preclinical: 10

• Clinical: 5

• Phase-I: 11

• Phase-I/II: 12

• Phase-II: 43

• Phase-II/III: 1

• Phase-III: 10

• Preregistration: 1

• Registered: 2

• Marketed: 30

1. Europe Breast Cancer Market Overview



2. Breast Cancer Drug Clinical Phase: Unknown Phase

  2.1 Overview

  2.2 Breast Cancer Drug Profile in Clinical Phase



3. Breast Cancer Drug Clinical Phase: Research

  3.1 Overview

  3.2 Breast Cancer Drug Profile in Clinical Phase



4. Breast Cancer Drug Clinical Phase: Preclinical

  4.1 Overview

  4.2 Breast Cancer Drug Profile in Clinical Phase



5. Breast Cancer Drug Clinical Phase: Clinical

  5.1 Overview

  5.2 Breast Cancer Drug Profile in Clinical Phase



6. Breast Cancer Drug Clinical Phase: Phase-I

  6.1 Overview

  6.2 Breast Cancer Drug Profile in Clinical Phase



7. Breast Cancer Drug Clinical Phase: Phase-I/II

  7.1 Overview

  7.2 Breast Cancer Drug Profile in Clinical Phase



8. Breast Cancer Drug Clinical Phase: Phase-II

  8.1 Overview

  8.2 Breast Cancer Drug Profile in Clinical Phase



9. Breast Cancer Drug Clinical Phase: Phase-II/III

  9.1 Overview

  9.2 Breast Cancer Drug Profile in Clinical Phase



10. Breast Cancer Drug Clinical Phase: Phase-III

  10.1 Overview

  10.2 Breast Cancer Drug Profile in Clinical Phase



11. Breast Cancer Drug Clinical Phase: Preregistration

  11.1 Overview

  11.2 Breast Cancer Drug Profile in Clinical Phase



12. Breast Cancer Drug Clinical Phase: Registered

  12.1 Overview

  12.2 Breast Cancer Drug Profile in Clinical Phase



13. Marketed Drugs
 
  13.1 Overview

  13.2 Marketed Drug Profile


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC Code

• Designated Brand Name